0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Lymphocytic leukaemia

Indication:

Dasatinib is indicated for the treatment of adult patients with: - Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XE
L01XE Protein kinase inhibitors
EMA approval status :
Approved
EMA approval date :
2006-11-20
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No